Sara Bringhen
A.O.U. Città della Salute e della Scienza
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Sara Bringhen as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:38 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT04096066 · A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for TransplantFondazione EMN Italy Onlus · active not recruiting · Multiple Myeloma, New Diagnosis Tumor · principal investigator
- Ph1/Ph2NCT02185820 · Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD)European Myeloma Network B.V. · completed · Multiple Myeloma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:38 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in multiple myeloma, ranked by citations from NIH iCite, fetched 2026-11-12 11:38 UTC. The ranking covers the 200 most relevant of 55 PubMed records, and a shared surname and initials can bring in a namesake. All 55 on PubMed
- 626 citationsRCR 14.5
- A comparison of allografting with autografting for newly diagnosed myeloma.N Engl J Med · 2007381 citationsRCR 8.4
- 356 citationsRCR 8.7
- 319 citationsRCR 8.2
- 283 citationsRCR 6.8
- Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.J Clin Oncol · 2011260 citationsRCR 7.4
- 252 citationsRCR 5.7
- Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network.J Clin Oncol · 2007243 citationsRCR 5.7
- 233 citationsRCR 7.0
- 184 citationsRCR 5.7